Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02851706 · ClinicalTrials.gov registry record
Natural History of and Specimen Banking for People With Tumors of the Central Nervous System
A clinical trial of Brain Tumor and Brain Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 1,214
- Enrollment target
- 1
- Study location
NCT02851706: Completed study of Brain Tumor and Brain Cancer, sponsored by National Cancer Institute (NCI).
NCT02851706 is a study of Brain Tumor and Brain Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 1,214 participants, above the 264-participant average among 69 other Brain Tumor trials with a reported enrollment target (360% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02851706, a study of Brain Tumor and Brain Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 1,214 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Brain and spinal cord tumors are uncommon. But they contribute substantially to cancer deaths in the U.S. in children and adults. Little progress has been made in treating brain tumors. Researchers want to learn more about these tumors by studying people who have them. Objectives: To understand brain and spinal cord tumors better and uncover areas for further research. Also, to connect people with these tumors to doctors who can help them manage their illness and give them new treatment options. Design: Participants will have an initial (baseline) visit. They will have their medical history taken and undergo physical and neurological exams. They will have blood tests. They may have scans (imaging studies) of the nervous system. If participants have urine or cerebrospinal fluid collected during their regular care, researchers may save some. Brain tumor tissue from a prior surgery may be studied. Genomic DNA testing will be done on samples. Results will be linked to participants medical and/or family history. The number of study visits at NIH will depend on the wishes of participants and their local doctors. Participants will take a brain tumor survey on a computer. They can take it all at once or in 6 separate sections. Participants will answer questions about their general well-being. They will answer questions to learn if they have symptoms of depression or anxiety. Physicians will discuss test results with participants. They will recommend management and treatment options.
Primary Outcome
Generalized knowledge about CNS tumors
Conditions Studied
Interventions
- OTHER No Treatment
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,214 participants |
| Start Date | 2016-09-01 |
| Est. Completion | 2025-05-29 |
What the finished NCT02851706 record still lists
NCT02851706 is an observational study that tracks outcomes without assigning an intervention. Its 1,214 participants enrollment target places it among the larger protocols in the corpus, above the 264-participant average among 69 other Brain Tumor trials with a reported enrollment target (360% higher).
The record links to 5 conditions, with Brain Tumor appearing as the primary indexed condition, and to 1 intervention - of which No Treatment is the first listed.
NCT02851706 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT02851706 about?
NCT02851706 is a clinical study titled "Natural History of and Specimen Banking for People With Tumors of the Central Nervous System". Background: Brain and spinal cord tumors are uncommon. But they contribute substantially to cancer deaths in the U.S. in children and adults. Little progress has been made in treating brain tumors. Researchers want to learn more about these tumors by studying people who have them. Objectives: To ...
What is the current status of trial NCT02851706?
This trial is currently completed. The enrollment target is 1,214 participants. The study started on 2016-09-01. Estimated completion is 2025-05-29.
What conditions does trial NCT02851706 study?
This clinical trial studies the following conditions: Brain Tumor, Brain Cancer, Neoplasm, Spine Tumor, Spine Cancer.
What interventions are being tested in trial NCT02851706?
The interventions under investigation include: No Treatment (OTHER).
Who is sponsoring clinical trial NCT02851706?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02851706 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02851706's enrollment target sits among peer trials
1,214 5th of 69 higher than 65 of 69 other Brain Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain
RECRUITING
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
RECRUITING · NA
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05827016 · 1,216 participants · Phase 3
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
- NCT06143956 · 1,217 participants · Phase 2
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- NCT04267848 · 1,210 participants · Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- NCT05946213 · 1,209 participants · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI